Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.

Official Title

A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors

Keywords

Advanced Cancer, Opdivo®, Immunotherapy, Paclitaxel, Carboplatin, Nivolumab, Pemetrexed, BMS-986406

Eligibility

You can join if…

Open to people ages 18 years and up

Parts 1A, 1B, 1C:

Part 1D:

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of non-squamous or squamous histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease, who have not had systemic therapy for metastatic or recurrent disease.

All Parts:

  • Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma)
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Adequate organ function

You CAN'T join if...

  • Prior organ or tissue allograft
  • Leptomeningeal metastases
  • Untreated CNS metastases
  • Serious or uncontrolled medical disorders

    Other protocol-defined inclusion/exclusion criteria apply

Locations

  • University California San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
    Los Angeles California 90025 United States
  • UCLA Health
    Los Angeles California 90404 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT05298592
Phase
Phase 1 Cancer, General Research Study
Study Type
Interventional
Participants
Expecting 154 study participants
Last Updated